Diamyd Medical
11.96 SEK
+1.01 %
Less than 1K followers
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.01 %
+6.22 %
+27.64 %
+9.12 %
+22.92 %
-32.95 %
-17.74 %
-58.70 %
+298.31 %
Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.
Read moreMarket cap
1.64B SEK
Turnover
5.09M SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28/1
2026
Interim report Q1'26
25/3
2026
Interim report Q2'26
24/6
2026
Interim report Q3'26
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
BioStock: Diamyd Medical accelerates its phase III timeline
DNB Carnegie Access: Diamyd Medical: Phase III timeline accelerated
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools